Traders Union
All News
Aging biology, drug discovery, and biotech research by BioAge Labs

Advertiser Disclosure

Aging biology, drug discovery, and biotech research by BioAge Labs

DeepOriginBio partnership accelerates BioAge Labs progress on human aging drug discovery

Igor Krasulya
15.10.2026

DeepOriginBio partnership accelerates BioAge Labs progress on human aging drug discovery

BioAge Labs has moved a new target for human aging from initial data to promising chemical matter within a matter of months. The company, collaborating with DeepOriginBio, has now validated the ...

BioAge Labs presents oral NLRP3 inhibition research on reversing aging effects in mice

Mykhailo Ihnatenko
28.09.2026

BioAge Labs presents oral NLRP3 inhibition research on reversing aging effects in mice

BioAge Labs has presented new research at the Mechanisms of Aging meeting at Cold Spring Harbor Laboratory, revealing findings on oral NLRP3 inhibition in aged mice. The company highlighted ...

Inflammation found to underlie cardiology, oncology, and other key fields as BioAge Labs, Inc. advances research

Andreas Kristo
30.07.2026

Inflammation found to underlie cardiology, oncology, and other key fields as BioAge Labs, Inc. advances research

BioAge Labs, Inc. draws attention to inflammation as a common element driving diseases across diverse medical fields. The statement echoes insight from Harvard cardiologist Peter Libby, featured ...

BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment

Ivan Andriyenko
10.07.2026

BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment

BioAge Labs, Inc. has launched QUELL-CV, a Phase 2 clinical study testing its oral NLRP3 inhibitor BGE-102 in adults with obesity and heightened cardiovascular risk. The move highlights BioAge ...

BioAge Labs, Inc. unveils new BioAge Podcast episode spotlighting longevity science progress

Artem Shendetskii
17.06.2026

BioAge Labs, Inc. unveils new BioAge Podcast episode spotlighting longevity science progress

BioAge Labs, Inc. has released a new episode of its BioAge Podcast, focusing on companies and researchers driving breakthroughs in the science of human longevity and drug discovery. The latest ...

BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week

Oleg Tkachenko
15.05.2026

BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week

BioAge Labs, Inc. CEO Kristin Fortney participated in a panel at Fierce Biotech Week Boston with R&D leaders from Amgen, Novo Nordisk, and Wave Life Sciences to examine the next frontier of ...

BGE-102 60 mg once daily achieves equivalent hsCRP reduction as 120 mg, BioAge Labs, Inc. finds

Igor Krasulya
21.04.2026

BGE-102 60 mg once daily achieves equivalent hsCRP reduction as 120 mg, BioAge Labs, Inc. finds

BioAge Labs, Inc. has released full Phase 1 data for BGE-102, its orally available and brain-penetrant NLRP3 inhibitor. The newly announced 60 mg once-daily cohort achieved profound reductions in ...

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.